GO:0008474 palmitoyl-(protein) hydrolase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008474 (palmitoyl-(protein) hydrolase activity) catalyzes the hydrolysis of palmitoyl-protein thioesters into palmitate and protein, reversing protein S-palmitoylation.
• PPT1 (palmitoyl-protein thioesterase 1) is the best-characterized enzyme carrying this activity, and its loss causes infantile neuronal ceroid lipofuscinosis (CLN1 disease).
• PPT1 is a lysosomal enzyme whose activity is pH-dependent and can be monitored with genetically encoded lysosomal pH sensors.
• PPT1 inhibitors such as GNS561 are clinical-stage anticancer agents that exploit lysosomal dysfunction in hepatocellular carcinoma.
• Serum PPT1 enzymatic activity correlates with schizophrenia diagnosis scales, suggesting a biomarker role.
• Beyond PPT1, PON1 also displays palmitoyl-protein thioesterase activity and influences SR-B1 membrane localization.
Description
Palmitoyl-(protein) hydrolase activity (GO:0008474) is a molecular function that removes the fatty acid palmitate from cysteine residues of substrate proteins through hydrolysis of a thioester bond. This reaction is the biochemical reverse of protein S-palmitoylation, a reversible lipid modification that controls protein membrane affinity, trafficking, and signaling. Because palmitoylation cycles are essential for neuronal and immune cell function, the enzymes that erase this mark are central to cellular homeostasis. Researchers study GO:0008474 to understand how dynamic lipidation shapes protein localization and to identify therapeutic targets in neurodegeneration, cancer, and metabolic disease. The best-known enzyme with this activity is PPT1, a lysosomal thioesterase mutated in CLN1 disease, but additional enzymes such as PON1 also display palmitoyl-protein thioesterase activity. Assays for this activity are used in diagnosis, drug discovery, and mechanistic studies of autophagy and lysosomal biology.
palmitoyl-(protein) hydrolase activity At A Glance
| GO ID | GO:0008474 |
|---|---|
| GO term | palmitoyl-(protein) hydrolase activity |
| Ontology | molecular_function |
| Synonym | palmitoyl-protein thioesterase activity; palmitoyl-protein hydrolase activity; palmitoyl-[protein] hydrolase |
| Major function | Hydrolysis of palmitoyl-protein thioesters to release palmitate and protein |
| Reaction | palmitoyl-protein + H2O = palmitate + protein |
| Representative enzyme | PPT1 (palmitoyl-protein thioesterase 1) |
| Subcellular context | Lysosome (for PPT1); also associated with membranes and serum |
| Disease relevance | CLN1 disease, cancer, schizophrenia, fibrosis |
What Is GO:0008474?
GO:0008474 describes the catalysis of the reaction palmitoyl-protein + H2O = palmitate + protein. In other words, it is the enzymatic removal of a palmitate group from a palmitoylated protein substrate, breaking a thioester bond and releasing free palmitate. The term is also known as palmitoyl-protein thioesterase activity or palmitoyl-protein hydrolase activity. It belongs to the molecular_function ontology and is distinct from palmitoyltransferase activity, which adds the palmitate group.
Why Is palmitoyl-(protein) hydrolase activity Important in Cell Biology?
Palmitoyl-(protein) hydrolase activity is important because it controls the reversible attachment of palmitate to proteins, a modification that dictates membrane targeting, protein-protein interactions, and signaling. Dysregulation of this activity is linked to severe neurodegenerative disease, cancer progression, and immune dysfunction. Measuring this activity in serum or cells can serve as a diagnostic or pharmacodynamic biomarker. Moreover, inhibitors of PPT1 are being developed as anticancer agents, highlighting the therapeutic potential of targeting this enzymatic function.
• Regulates reversible S-palmitoylation, affecting protein trafficking and membrane association.
• PPT1 loss-of-function mutations cause infantile neuronal ceroid lipofuscinosis (CLN1 disease).
• PPT1 inhibitors such as GNS561 show efficacy against hepatocellular carcinoma by modulating lysosomal functions.
• Serum PPT1 activity correlates with schizophrenia symptom scales, suggesting a biomarker role.
• PPT1 is involved in macrophage autophagy and aging-related myocardial fibrosis through gut metabolite signaling.
• Palmitoyl-protein thioesterase activity of PON1 affects SR-B1 localization on endothelial cell membranes.
• The activity is relevant to melanoma autophagy and lysosomal biology.
• Assays for this activity support drug discovery and mechanistic studies of lysosomal storage disorders.
What Happens During palmitoyl-(protein) hydrolase activity?
Substrate recognition and binding
In simple terms: The enzyme finds and grabs onto a protein that has a palmitate fat attached.
Palmitoyl-(protein) hydrolases recognize substrate proteins that carry a palmitate group linked via a thioester bond to cysteine residues. For PPT1, substrate recognition occurs in the lysosome, where the enzyme encounters palmitoylated proteins delivered by autophagy or endocytosis. The binding step is influenced by the hydrophobic palmitate chain and the protein context.
Thioester bond cleavage
In simple terms: The enzyme cuts the bond between the fat and the protein using water.
The catalytic mechanism involves nucleophilic attack on the thioester carbonyl, leading to hydrolysis and release of free palmitate and the de-palmitoylated protein. This reaction is the biochemical reverse of palmitoylation and is essential for recycling palmitate and regulating protein function.
Product release and recycling
In simple terms: After cutting, the enzyme lets go of the fat and the protein, which can then be reused or degraded.
Following hydrolysis, palmitate is released and can be recycled or degraded, while the modified protein may undergo changes in localization or stability. In lysosomes, PPT1-mediated depalmitoylation contributes to the degradation of palmitoylated proteins and to lysosomal homeostasis.
Regulation by pH and cellular context
In simple terms: The enzyme works best in the acidic environment of the lysosome.
PPT1 activity is optimal at acidic pH, consistent with its lysosomal localization. Live imaging of intra-lysosome pH using genetically encoded biosensors has shown that lysosomal pH dynamics can influence hydrolase activity. Cellular stress, such as oxidative stress or nutrient deprivation, can also modulate this activity.
Key Genes Involved in GO:0008474 palmitoyl-(protein) hydrolase activity
The following genes and proteins are directly associated with palmitoyl-(protein) hydrolase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPT1 | Lysosomal palmitoyl-protein thioesterase that removes palmitate from proteins | Mutations cause CLN1 disease; target for cancer therapy |
| PON1 | Paraoxonase with palmitoyl-protein thioesterase activity | Affects SR-B1 membrane localization in endothelial cells |
| CLN3 | Lysosomal transmembrane protein linked to CLN3 disease | May interact with PPT1 pathways in lysosomal function |
| CLN5 | Lysosomal protein involved in neuronal ceroid lipofuscinoses | Potential modifier of PPT1-related pathology |
| GNS561 | Clinical-stage PPT1 inhibitor (drug, not gene) | Anticancer activity via lysosomal modulation |
| SR-B1 | Scavenger receptor affected by PON1 activity | Endothelial membrane dynamics |
| MAP1LC3B | Autophagy marker influenced by PPT1-mediated pathways | Macrophage autophagy and fibrosis |
| mTOR | Kinase regulating autophagy and lysosomal biogenesis | Upstream regulator of lysosomal hydrolase expression |
| TFEB | Transcription factor controlling lysosomal and autophagy genes | Master regulator of lysosomal hydrolase expression |
| SQSTM1 | Autophagy receptor degraded in lysosomes | Readout of lysosomal degradation capacity |
| CTSB | Lysosomal protease | General lysosomal function marker |
| LAMP1 | Lysosomal membrane protein | Lysosomal abundance marker |
| ATP6V1A | V-ATPase subunit controlling lysosomal pH | Regulates pH-dependent hydrolase activity |
| GBA1 | Lysosomal glucocerebrosidase | Related lysosomal storage disorder gene |
| NPC1 | Lysosomal cholesterol transporter | Lysosomal function and disease context |
| BECN1 | Autophagy initiation protein | Crosstalk with lysosomal hydrolase pathways |
How Is palmitoyl-(protein) hydrolase activity Regulated?
Palmitoyl-(protein) hydrolase activity is regulated at multiple levels. Transcription of PPT1 and other lysosomal hydrolases is controlled by the TFEB/mTORC1 axis, which senses nutrient status and promotes lysosomal biogenesis. Lysosomal pH, maintained by the V-ATPase, directly influences PPT1 catalytic efficiency. Additionally, post-translational modifications and substrate availability can modulate activity. In disease contexts, such as cancer, PPT1 expression and activity can be altered, and inhibitors like GNS561 can block its function. Gut metabolites such as indole-3-propionic acid can also regulate PPT1-dependent autophagy in macrophages.
palmitoyl-(protein) hydrolase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPT1 | CLN1 disease (infantile neuronal ceroid lipofuscinosis) | PPT1 knockout neurons; patient iPSC-derived neurons |
| PPT1 | Hepatocellular carcinoma | HCC cell lines treated with GNS561; xenograft models |
| PPT1 | Schizophrenia | Serum enzyme activity assays in patient cohorts |
| PPT1 | Myocardial fibrosis | Macrophage-specific Ppt1 knockout mice; aging models |
| PON1 | Endothelial SR-B1 regulation | PON1 knockout endothelial cells; overexpression models |
Neurodegeneration: CLN1 disease
Biallelic mutations in PPT1 cause infantile neuronal ceroid lipofuscinosis (CLN1 disease), a fatal neurodegenerative disorder characterized by lysosomal accumulation of autofluorescent storage material and progressive neuronal loss. Loss of palmitoyl-(protein) hydrolase activity leads to impaired degradation of palmitoylated proteins and lysosomal dysfunction.
Cancer: hepatocellular carcinoma and beyond
PPT1 is overexpressed in several cancers and supports lysosomal function and autophagy, promoting tumor survival. The clinical-stage PPT1 inhibitor GNS561 is efficient against hepatocellular carcinoma by modulating lysosomal functions, demonstrating the therapeutic potential of targeting this activity. In melanoma, autophagy and lysosomal pathways are emerging as key vulnerabilities.
Schizophrenia and neuropsychiatric disorders
Serum palmitoyl-protein thioesterase-1 activity is significantly associated with schizophrenia diagnosis scales, suggesting that this enzymatic activity may serve as a peripheral biomarker. The mechanistic link may involve altered lipid metabolism and protein palmitoylation in the brain.
Cardiac fibrosis and aging
The gut metabolite indole-3-propionic acid regulates macrophage autophagy through PPT1, inhibiting aging-related myocardial fibrosis. This highlights a role for palmitoyl-(protein) hydrolase activity in age-related cardiovascular disease and immune-metabolic crosstalk.
From palmitoyl-(protein) hydrolase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PPT1 impair lysosomal degradation? | PPT1 knockout cell lines (e.g., HeLa, SH-SY5Y) |
| Does a specific patient mutation affect enzyme activity? | Point-mutation knock-in of mutant PPT1 |
| Can tagged PPT1 rescue phenotypes? | Knock-in of fluorescently tagged PPT1 |
| Does PPT1 overexpression enhance autophagy? | PPT1 overexpression in cancer cell lines |
| What is the effect of PPT1 inhibition on tumor growth? | Xenograft models treated with GNS561 |
| How does PON1 affect SR-B1 localization? | PON1 knockout or overexpression in endothelial cells |
How to Study the palmitoyl-(protein) hydrolase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorogenic thioesterase assay | Palmitoyl-protein hydrolase activity | Serum or cell lysate enzyme activity |
| Activity-based protein profiling (ABPP) | Active serine hydrolases including PPT1 | Proteome-wide hydrolase profiling |
| Live lysosomal pH imaging | Intra-lysosomal pH | Monitoring pH-dependent hydrolase function |
| Western blot for LC3B/SQSTM1 | Autophagic flux | Assessing lysosomal degradation capacity |
| Immunofluorescence for LAMP1 | Lysosomal abundance and morphology | Lysosomal storage and dysfunction |
| CRISPR knockout screening | Gene essentiality and pathway dependencies | Identifying modifiers of PPT1 activity |
| RNA-seq | Transcriptional changes | TFEB/mTOR pathway activation |
| Xenograft tumor growth | In vivo efficacy of PPT1 inhibitors | Preclinical drug testing |
Enzymatic activity assays
Palmitoyl-(protein) hydrolase activity can be measured using fluorogenic or radioactive substrates that mimic palmitoyl-protein thioesters. These assays are used to quantify activity in serum, cell lysates, or purified enzyme preparations.
Live-cell imaging of lysosomal pH
Genetically encoded pH biosensors targeted to lysosomes allow real-time monitoring of lysosomal pH, which directly affects PPT1 activity. This method is useful for studying how perturbations alter hydrolase function.
Proteomics and activity-based protein profiling
Activity-based protein profiling (ABPP) with serine hydrolase probes can detect changes in hydrolase activities, including palmitoyl-protein thioesterases, in complex proteomes. SWATH/DIA-MS enables quantification of lipid remodeling associated with hydrolase activity.
Autophagy and lysosomal flux assays
LC3B lipidation, SQSTM1 degradation, and lysosomal mass can be assessed by western blot and imaging to infer changes in lysosomal hydrolase function. These assays are often combined with PPT1 inhibition or knockout.
How CRISPR Can Be Used to Study GO:0008474 palmitoyl-(protein) hydrolase activity
Knockout
CRISPR knockout of PPT1 in cell lines such as HeLa or SH-SY5Y abolishes palmitoyl-(protein) hydrolase activity, leading to lysosomal storage and impaired autophagy. These models are used to study CLN1 disease mechanisms and to test rescue strategies.
Point Mutation
Knock-in of patient-derived point mutations (e.g., R122W, T75P) into the endogenous PPT1 locus allows assessment of mutation-specific effects on enzyme activity, stability, and lysosomal function. Such models are valuable for genotype-phenotype correlations.
Knock-in
Knock-in of epitope tags or fluorescent proteins (e.g., GFP) at the PPT1 locus enables live-cell imaging and proteomic analysis of the enzyme. Tagged knock-in models help track subcellular localization and dynamics.
Overexpression
CRISPR activation or lentiviral overexpression of PPT1 can enhance palmitoyl-(protein) hydrolase activity, which may promote autophagy and affect cancer cell survival. Overexpression models are useful for studying gain-of-function effects and drug resistance.
How EDITGENE Supports palmitoyl-(protein) hydrolase activity Research
Researchers studying palmitoyl-(protein) hydrolase activity-related genes often need to determine whether a candidate gene is causally involved in lysosomal function, autophagy, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous mechanistic and translational studies.
Contact EDITGENE today to design your custom CRISPR model for palmitoyl-(protein) hydrolase activity research.
Frequently Asked Questions About palmitoyl-(protein) hydrolase activity
What is palmitoyl-(protein) hydrolase activity?
It is the enzymatic activity that removes palmitate from proteins by hydrolyzing a thioester bond, encoded by GO:0008474.
What genes are involved in palmitoyl-(protein) hydrolase activity?
PPT1 is the primary gene, and PON1 also exhibits this activity.
What is the role of PPT1 in disease?
PPT1 mutations cause CLN1 disease, and PPT1 is implicated in cancer, schizophrenia, and fibrosis.
How is palmitoyl-(protein) hydrolase activity measured?
Common methods include fluorogenic thioesterase assays, activity-based protein profiling, and live lysosomal pH imaging.
What is the connection between PPT1 and autophagy?
PPT1 supports lysosomal degradation and autophagy; its inhibition or loss impairs autophagic flux.
Can PPT1 be targeted for cancer therapy?
Yes, PPT1 inhibitors such as GNS561 show anticancer activity in hepatocellular carcinoma models.
What is CLN1 disease?
CLN1 disease is a fatal neurodegenerative lysosomal storage disorder caused by PPT1 deficiency.
Does PON1 have palmitoyl-protein thioesterase activity?
Yes, PON1 displays this activity and can affect SR-B1 localization on endothelial cells.
How does lysosomal pH affect PPT1 activity?
PPT1 is optimized for the acidic lysosomal environment, and pH changes can alter its activity.
What CRISPR models are available for studying PPT1?
Knockout, point mutation knock-in, tagged knock-in, and overexpression models can be generated.
Conclusion
Palmitoyl-(protein) hydrolase activity (GO:0008474) is a fundamental enzymatic function that reverses protein S-palmitoylation, with critical roles in lysosomal biology, autophagy, and disease. PPT1 is the archetypal enzyme, and its dysfunction leads to CLN1 disease, while its inhibition shows promise in cancer therapy. Continued research using CRISPR models and advanced proteomics will further illuminate the therapeutic potential of targeting this activity.
References
- 1. Sajic T et al.. 2025. Depletion-dependent activity-based protein profiling using SWATH/DIA-MS detects serine hydrolase lipid remodeling in lung adenocarcinoma progression.. Nat Commun 16(1):4889 PMID: 40425563
- 2. Lu J et al.. 2025. Gut Metabolite Indole-3-Propionic Acid Regulates Macrophage Autophagy Through PPT1 Inhibiting Aging-Related Myocardial Fibrosis.. Adv Sci (Weinh) 12(34):e01070 PMID: 40539882
- 3. Brun S et al.. 2022. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.. Autophagy 18(3):678-694 PMID: 34740311
- 4. Wu Y et al.. 2019. Enzymatic activity of palmitoyl-protein thioesterase-1 in serum from schizophrenia significantly associates with schizophrenia diagnosis scales.. J Cell Mol Med 23(9):6512-6518 PMID: 31270934
- 5. Pangilinan C et al.. 2024. Emerging dimensions of autophagy in melanoma.. Autophagy 20(8):1700-1711 PMID: 38497492
- 6. Ponsford AH et al.. 2021. Live imaging of intra-lysosome pH in cell lines and primary neuronal culture using a novel genetically encoded biosensor.. Autophagy 17(6):1500-1518 PMID: 32515674
- 7. Barnes M et al.. 2026. Palmitoyl-protein thioesterase-1 in health and disease.. Trends Pharmacol Sci 47(3):248-262 PMID: 41741265
- 8. Ashkar R et al.. 2024. PON1 has palmitoyl-protein thioesterase (PPT) activity, and can affect the presence of SR-B1 on the endothelial cell membrane.. Biofactors 50(3):608-618 PMID: 38135490
